Core Insights - The National Healthcare Security Administration (NHSA) has included 114 new drugs in the national basic medical insurance catalog, covering various fields such as oncology, anti-infection, and chronic diseases [1][3] - The newly added drugs include significant innovations like GLP-1 diabetes medication Tirzepatide and long-acting growth hormone product Ipexi [1][3] - A new commercial health insurance innovation drug catalog has been introduced, featuring 19 products, including CAR-T therapies and new Alzheimer's drugs, aimed at addressing the payment challenges of high-priced innovative drugs [3][4] Summary by Category New Drug Additions - The updated medical insurance catalog includes drugs for chronic diseases, such as Tirzepatide for diabetes and Inclisiran for cholesterol reduction [1][2] - Other notable inclusions are Dupilumab for atopic dermatitis and the flu drug Masitinib [1] Pricing and Discounts - Although the NHSA did not disclose average price reductions, it is speculated that the discount rates may align with previous years' reductions of 50%-60% [3] - The long-acting growth hormone Ipexi is reported to have a price of approximately 850 yuan per injection, reflecting a nearly 50% reduction [3] Commercial Health Insurance Catalog - The commercial health insurance catalog aims to resolve the payment difficulties associated with high-priced innovative drugs, with 19 products included, of which 5 are CAR-T therapies [3][4] - The discount range for these products is between 15%-50%, slightly higher than the previously expected 30% [3][4] Market Dynamics and Implications - The inclusion of CAR-T therapies in the commercial insurance catalog marks a significant development, providing a national reimbursement pathway for these high-cost treatments [4][5] - The commercial insurance catalog's products benefit from a "three exclusions" policy, which allows for more favorable pricing and reimbursement conditions [4][6] Future Outlook - The introduction of the commercial insurance catalog is seen as a first step, with the focus now shifting to its implementation and integration with existing health insurance products [8][10] - The "Hui Min Bao" insurance products are expected to play a crucial role in accommodating the new catalog, with many products already providing coverage for CAR-T therapies [9][10] - The NHSA emphasizes a collaborative approach between basic medical insurance and commercial insurance, aiming for a complementary rather than competitive relationship [11]

文章称，10月30日至11月3日，国家医保局组织开展2025年国家基本医保药品目录谈判竞价和商保创新药目录价格协商工作，120家内外资企业现场参与， 其中参与基本医保药品目录谈判竞价的目录外药品127个，参与商保创新药目录价格协商的药品24个。 文章表示："希望医保、医疗、医药携手，共同促进医药技术创新发展，让更多新药好药尽快惠及患者，为健康中国建设贡献力量。" 文章提到，"后续相关技术、行政和法律程序完成后，新版基本医保药品目录及首版商保创新药目录拟于12月第一个周末在广州线上线下（300959）同步 发布，明年1月1日起正式实施，请大家保持关注"。 对此，中信证券医药健康行业首席分析师陈竹对记者表示："看图片和标题，目标很明确！" 此前，国家医保局与国家卫健委联合发布了《支持创新药高质量发展的若干措施》，其中，"建立商保创新药目录"成为业内关注的焦点。对此，国家医保 局在后续的新闻发布会上表示，将通过该目录"做好医保药品目录和商保创新药目录的衔接，为商保创新药提供稳定出口，提高药品可及性"。 数据显示，2023年我国创新药支付结构中，个人自付占49%、基本医保占44%、商业健康保险仅占7%。 【导读】首版 ...